Gordon Chan

549 posts

Gordon Chan

Gordon Chan

@GordonChan4008

喜歡簡單而寫意嘅生活

Hong Kong Katılım Şubat 2024
106 Takip Edilen44 Takipçiler
Gordon Chan
Gordon Chan@GordonChan4008·
@investseekers @dma0040 Based on the performance of $NVO today, if the pricing close to US$50 before earning report, I will reduce the position of $NVO again.......
English
0
0
0
74
Investseekers
Investseekers@investseekers·
Consensus expects $NVO to report Q2 revenue of DKK 71.3B and adjusted EBIT of DKK 28.7B when it reports earnings on Wednesday. Analysts expect continued weakness in the diabetes franchise, with Ozempic sales of DKK 26.7B, down from DKK 30.5B a year ago, and Rybelsus sales of DKK 4.7B versus DKK 5.6B. Obesity is expected to remain the bright spot. Analysts forecast Wegovy sales of DKK 19.1B, while Oral Wegovy is expected to contribute another DKK 3.3B in just its second reported quarter.
English
3
3
53
6.1K
Gordon Chan
Gordon Chan@GordonChan4008·
@investseekers BAD NEWS again.....For the coming earning report, we may facing the other bad news.....
English
1
0
2
356
Investseekers
Investseekers@investseekers·
$NVO reported that its Phase 3 ZEUS study of ziltivekimab failed to reduce the risk of heart attacks, strokes, or cardiovascular death. Although the drug successfully lowered inflammation, it did not improve cardiovascular outcomes compared with placebo in patients with cardiovascular disease and chronic kidney disease. Novo Nordisk said the result will not change its 2026 operating profit outlook but will result in a non cash impairment charge in Q3. The company also confirmed that two other late stage studies of ziltivekimab in heart failure and heart attack patients will continue, with results expected in the first half of 2027. Link: novonordisk.com/content/nncorp… #stocks #Investing
English
7
2
54
8.3K
Gordon Chan
Gordon Chan@GordonChan4008·
@novonordisk OMG.....any BAD news for $NVO , it must drop 10% of stock price...... For the coming earning report, the second BAD news may be released.....
English
0
0
1
397
Jowi Pozo
Jowi Pozo@JowiPozoX·
6. $INTU - Intuit → Soluciones financieras y contables para empresas y particulares.
Jowi Pozo tweet mediaJowi Pozo tweet media
Español
2
0
2
1.5K
Jowi Pozo
Jowi Pozo@JowiPozoX·
6 acciones que los Mejores Inversores del Mundo están comprando para aprovechar el crecimiento del software empresarial: 1. $MSFT - Microsoft → Software empresarial, nube e inteligencia artificial.
Jowi Pozo tweet mediaJowi Pozo tweet media
Español
24
22
103
17.8K
Rene Jeppesen
Rene Jeppesen@JeppesenRj·
We are now at over 300,000 weekly, and when we include the UAE, the UK, and the EU from 2027, that figure will be at least 500,000 per week, possibly double. 500,000 × 4 weeks = 2 million × 12 months = 24 million × an average of DKK 1,000 That amounts to DKK 24 billion per year from tablets alone. But it will probably be twice that.
English
1
0
2
225
Gordon Chan
Gordon Chan@GordonChan4008·
@Aktieland We are looking for the Q2 earning report and prove that $NVO still growing up in the market. HOPE we can meet the first price target around USD $53-$55/share.
English
0
0
1
125
Aktieland
Aktieland@Aktieland·
📈 The oral GLP-1 battle has a clear leader—for now. Weekly prescriptions: 🔵 Wegovy pill: ~165K 🔴 Foundayo: ~22K The race is far from over, but today the scoreboard clearly favors $NVO. #GLP1 #NovoNordisk #Investing $LLY $HIMS
Aktieland tweet media
English
2
3
42
1.3K
Gordon Chan
Gordon Chan@GordonChan4008·
@Redpulse_News The most important that is Buying Vol. It needs more buying power to increase the stock price. If the Q2 earning report meet the expectation and upgrade the 2026 revenue, then $NVO will up to $53 to $55.
English
0
0
3
179
Redpulse
Redpulse@Redpulse_News·
$NVO is days away from a Golden Cross. The last time this happened, it ran 140% in 18 months and was still up 96% before it fell into a death cross. It might be time...
Redpulse tweet mediaRedpulse tweet mediaRedpulse tweet media
English
3
0
30
2.8K
Redpulse
Redpulse@Redpulse_News·
$NVO is at 310.6 DKK ($47.39756 USD) in Copenhagen at the open.
English
1
0
6
1.1K
Gordon Chan
Gordon Chan@GordonChan4008·
@investseekers But I found the BIG DROP (-1.85%) for $NVO. Roche affect the earning report (Q22026) for $NVO ? $NVO
English
0
0
0
454
Investseekers
Investseekers@investseekers·
$NVO Roche reported better than expected Q2 sales for its hemophilia drug Hemlibra. Hemlibra generated CHF 1.30 billion in sales, up 9% year over year and ahead of Bloomberg consensus of CHF 1.23 billion. Hemlibra competes with Novo's NovoSeven in hemophilia, making the stronger than expected performance relevant for Novo Nordisk investors. #stocks #Investing
English
4
0
21
4.2K
Gordon Chan
Gordon Chan@GordonChan4008·
@TzerKran @TJ_Research 直播不會告訴你割肉還是持有。重點是你倉位有多重,如果不是重倉,那為什麼要割肉?
中文
0
0
0
347
KranTzer
KranTzer@TzerKran·
@TJ_Research 有没有吊大的兄弟看直播告诉我答案,是割肉还是持有😭
中文
2
0
0
1.7K
Gordon Chan
Gordon Chan@GordonChan4008·
@StockChaser_ Haha, I just need $NVO up 86%, and I will sell out all of them🤣🤣🤣🤣🤣
English
0
0
0
247
StockChaser
StockChaser@StockChaser_·
Keep an eye on this $NVO is about to form a golden cross The last time it did, it ran 172% Will history repeat? Let's see
StockChaser tweet media
English
23
15
115
18.5K
Gordon Chan
Gordon Chan@GordonChan4008·
@Aktieland Actually, I hope we can get the BIG returns from $NVO. 🥳🥳🥳
English
0
0
3
72
Aktieland
Aktieland@Aktieland·
@GordonChan4008 That's exactly why I think $NVO may be the most attractive opportunity among them. Price to perfection vs. price to pessimism.
English
2
0
3
94
Aktieland
Aktieland@Aktieland·
It wasn't a good week for healthcare, yet $NVO outperformed much of the sector. Weekly performance: $AZN -10.3% $ABBV -5.0% $MRK -4.6% $ISRG -4.5% $AMGN -2.9% $JNJ -2.3% $LLY -2.1% $NVO -1.4% Relative strength is often one of the first signs that sentiment is starting to shift.
Aktieland tweet media
English
3
0
15
1K
Investing visuals
Investing visuals@InvestingVisual·
Top 10 holdings of Cathy Wood's ARKK portfolio: • $TSLA - 10% • $TEM - 7% • $CRSP - 5% • $HOOD - 5% • $AMD - 4% • $SHOP - 4% • $SPCX - 4% • $COIN - 4% • $TWST - 4% • $RBLX - 3%
Investing visuals tweet media
English
9
31
168
35.8K
Gordon Chan
Gordon Chan@GordonChan4008·
@investseekers Then, how can we get the sell through in UK market? Thanks Bro
English
0
0
0
27
Investseekers
Investseekers@investseekers·
Early demand for $NVO 's oral Wegovy appears to be strong in the UK. According to a survey by the National Pharmacy Association, 71% of UK pharmacies have already received enquiries from patients looking to start treatment just days after launch. "The demand has definitely been noticeable," said National Pharmacy Association Chair Olivier Picard. Another pharmacist described a "significant increase" in enquiries, adding: "There has been a real buzz and a lot of excitement." Oral Wegovy became available through UK private pharmacies this week following its recent approval. Link to article: ft.com/content/5bb61b… #stocks #Investing
English
1
1
45
3.3K
Gordon Chan
Gordon Chan@GordonChan4008·
@caoliw @jason_chen998 因為大家都了解當中的便利性,發展空間和前景。市場這麼大,當然多競爭者入市場。
中文
0
0
0
196
陈剑Jason
陈剑Jason@jason_chen998·
全球最大的金融网络Swift在今天宣布开发的区块链已经正式上线,首批接入了17家银行开展24/7代币化存款的跨境支付,从而实现秒到账,不再需要等待各个不同国家银行的营业时间,并且号称每3天就可以在200多个国家转移全球GDP的资金,这是传统金融体系对区块链和代币化迈出最大的一步,但也只能说迈出了半步,毕竟依然用的是联盟链,不过这也情有可原,但是转移的资金也依然不是USDT、USDC等任何一个稳定币,而是银行自己的代币化存款,只在Swift银行体系内部流转,所以这是以Swift牵头全球银行联合发起的一场防御反击战。 毕竟稳定币实时转账的优势摆在这里,如果Swift和银行再不行动,则很多企业会选择把银行存款换成稳定币,银行会失去存款,而Swift也会失去结算地位,所以Swift就拉着这些银行把自己的存款代币化,至少保证在原有体系里的资金不会流出去。
陈剑Jason tweet media
中文
63
32
187
62.3K
Aktieland
Aktieland@Aktieland·
Trading volume in Novo Nordisk remains surprisingly low. After roughly two hours of trading, only 1.8 million shares have changed hands versus an average daily volume of 14.8 million. That doesn't suggest broad-based panic selling. $NVO #NovoNordisk
Aktieland tweet media
English
2
0
8
968
Gordon Chan
Gordon Chan@GordonChan4008·
@AlphaBeta_2017 @bullrunalpha It is because $Coin and $CRCL will review the working contract on Aug,2026. May be $Coin want to increase the bargaining power when dealings with $CRCL.
English
0
0
1
38
Eigen
Eigen@AlphaBeta_2017·
@bullrunalpha Why does $COIN join the consortium? I don’t get it.
English
1
0
1
214
Adam
Adam@bullrunalpha·
$CRCL — Open USD is dead in the water as a competitive threat to $USDC. 🚩 Gridlock: 140+ corporate rivals can't manage fast network changes. Big firms need speed, not committee delays. 🚩 Starved: Safe networks cost $500M+ OPEX. OUSD’s zero-profit model simply can't fund it.
Lorenzo Valente@LorenzoARK

Every year we get our consortium style initiative around a stablecoin, we have seen this with Diem, Global dollar and now Open USD. While the set of players here is obviously potent, I remain highly skeptical any of these initiatives can hit scale. A few thoughts on OpenUSD: 1. Liquidity and the cold-start problem. USDC and USDT have massive network effects across exchanges, payment processors, and brokers. This is always repeated but it's true, there are no BTC/sofiUSD pairs to trade on any of these exchanges or markets. These are not stableocin market makers and participants are willing to hold in size, as you can’t really use them anywhere. The fair counter is that crypto markets will be far smaller than remittances or equities/bonds. Probably true, I suspect in the medium term, but those markets are still converging on the same stablecoins. Hyperliquid just struck a massive deal with USDC/Coinbase. Every tokenization initiative so far is built around the incumbents too. 2. A consortium of 500 rivals has no precedent for working. The pace of decision-making across 500 competitors is going to be glacial. Not everyone gets a board seat at Open Standard I imagine, so what happens when decisions cut against some of the players? Circle and Tether ship whatever they want, whenever they want, with zero commitment to anyone. 3. Regulatory and antitrust risk at scale. Circle and Tether are willing to absorb enormous pressure, they have being doing so for years. They hold hundreds of licenses they can use to arbitrage markets, Yes GENIUS act gave a lot of breathing room and clarity, but oversees, this is not the same story. The moment this gets hard under regulatory pressure, I think a lot of these partners just walk away. And a bloc of the largest banks and card networks jointly issuing money is an obvious antitrust target. 4. The "socialist" economics starve the issuer. Passing reserve revenue back to partners sounds great in practice, but what does Open Standard actually operate on? Little to no retained capital. People forget Circle doesn't just have marketplace/exchange partnerships; it funds a whole web of rebates across on/off ramps, stablecoin settlement, OTC desks, and more, with each deal being somewhat bespoke depending not he partner. Who funds that at Open Standard? Who decides which deals, on what terms, especially when the counterparty is a rival of an existing member? Circle GAAP Opex for 2025 were 900M USD, if you strip out one time cost and IPO related cost, its adjusted OPEX is closer to 500M annually. Let’s say open Standard gets 25 bips, which is what other consortium did, At 10B of supply, open standard is making 25M a year… You don’t fund much with that…. You need to become huge very quickly. 5. The announcement is basically a giant LOI. Read the quotes: BlackRock calls it "a constructive step," BNY "looks forward to exploring ways to support," others say it's "interesting." Meanwhile the partners are backing rivals: Stripe owns Bridge and has its own stack, Coinbase is wedded to USDC, banks are building their own deposit tokens, and the card networks support every token out there. They'll hedge across all of them. Distribution only matters if it's exclusive — and it clearly won't be. 6. The "mint/redeem fees are a problem" claim is wrong. In practice every large institution minting and redeeming through Circle and Tether already gets big rebates. The real cost of moving money is FX, not mint/redeem and there's no moat there, because anyone can just match free mint/redeem. All in all: one to monitor, but I'm deeply skeptical that an organization that looks like a DAO of 500 companies can move fast enough to matter long term. Who decides go-to-market? Capital allocation? Anything? Ultimately this reminds me of the DAO experiment. The pitch was identical: no single owner, "neutral" governance, aligned incentives, decisions made collectively for the good of the network. In practice DAOs almost universally failed at the thing that actually matters: shipping. Governance turned into endless forum debates and token-weighted voting where nothing decisive got done, capital sat idle because no one could agree how to deploy it, and the projects that won were the ones with a clear owner willing to move fast and take risk. "Owned by everyone" almost always means accountable to no one. Open Standard is a DAO of competitors that are not really committed to anything, and I'd bet on the two operators who can ship unilaterally over a committee that has to ask 500 rivals for permission.

English
8
21
126
22.6K
Gordon Chan
Gordon Chan@GordonChan4008·
@Artem_Oak How about -20% per day?What will he say later 🤔
English
0
0
1
98